{
  "@context": "https://frontierpicks.com/schemas/dossier.v1.json",
  "ticker": "HELP",
  "name": "Cybin Inc.",
  "url": "https://frontierpicks.com/dossiers/HELP/",
  "json_url": "https://frontierpicks.com/dossiers/HELP.json",
  "status": "DORMANT",
  "current_conviction": "LOW",
  "graded_conviction": "LOW",
  "archetype": {
    "code": "a6",
    "n": 6
  },
  "current_thesis": "Post-dilution CNS microcap re-firing with the psychedelic cohort (ATAI, CMPS all moving 2026-07-16) after a June social-velocity blowoff and a 10.3M-share secondary at $4.85. Both covering shops cut targets in July while holding Buy. No dated catalyst — APPROACH Phase 3 reads out years out. Wants a base above $4.85 before it's tradable.",
  "invalidation_trigger": "A daily close below $4.85 — back through the 2026-06-24 secondary-offering price — puts the entire offering book underwater and confirms the social-velocity melt-up has fully unwound with no support structure beneath it.",
  "catalyst_date": null,
  "outcome": "PLAYED_OUT",
  "outcome_date": "2026-08-06",
  "invalidation_fired": false,
  "themes": [
    "precision-biotech-therapeutics"
  ],
  "tags": [],
  "sources": [],
  "notes": [
    "2026-07-16: HELP printed as a gainer alongside ATAI and CMPS in two separate screens — the cohort is the correlation risk; single-name analysis understates it.",
    "Legal entity is Cybin Inc., operating as Helus Pharma; a Canadian line trades as HELP.NE alongside the Nasdaq line and the two can diverge intraday on FX and liquidity.",
    "Foreign private issuer: reports on Form 6-K and insiders file to Canada's SEDI rather than SEC Form 4, so US insider-transaction screens show no activity by construction.",
    "Fiscal year ends 31 March. The 2026-08-14 release was fiscal Q1 2027, covering the quarter ended 2026-06-30 — not a calendar Q1.",
    "Company guidance for APPROACH topline is 'Q4 2026' with no scheduled date; the mid-November timing comes from TD Cowen's 2026-08-20 note, not from the company.",
    "Float is 46.84M of 61.98M shares outstanding (2026-08-15). A micro float gaps in both directions; a session can open far from the prior close.",
    "Cash was $166.4M at 2026-06-30 against $37.1M of operating cash used in that quarter; the release carries no explicit runway statement."
  ],
  "body_markdown": "## Current Thesis\nThe August development is not a new clinical datapoint — it is a covering shop putting a month on the binary. On 2026-08-20 TD Cowen maintained Buy and raised its target from $8 to $62, citing three grounds: \"increased visibility into the timing of Phase 3 HLP003 adjunct major depressive disorder data, now expected in mid-November 2026,\" the 2026-08-03 CEO appointment, and M&A, regulatory and executive-branch developments across psychedelic neuropsychiatry. Shares rose roughly 6% that session; the 2026-08-21 close of $12.59 is the 52-week high, with RSI(14) at 76.2 and a three-month price change of +169%.\n\nMEASURED: the company's own guidance for APPROACH topline remains \"Q4 2026\" with no scheduled date (2026-07-21 release). INFERRED: the tape is now trading the analyst's narrower mid-November window rather than the company's quarter-wide one, which is why a target revision with no accompanying data moved the quote.\n\nThe classification has shifted since the June melt-up. This behaves as a binary-catalyst equity rather than a squeeze: short interest of 3.15M shares, 6.73% of float, and a short ratio of 1.99 as of 2026-08-15 are not squeeze mechanics. The narrative is **accelerating**, dated by a chain of fresh headlines — 2026-07-21 enrollment completion, 2026-07-27 Wells Fargo initiation, 2026-08-03 CEO, 2026-08-18 Chief People Officer and Scientific Advisory Board additions, 2026-08-20 target hike, 2026-08-21 new closing high. Attention and coverage are expanding. Price structure is doing nothing to absorb it.\n\n## Bull Case\n- **2026-08-20:** TD Cowen Buy maintained, price target $8 → $62 (a 7.75x revision). Coverage of the note cited a street target range of $8.15 to $70.45, with H.C. Wainwright at $70 and Canaccord at $42.\n- **2026-07-21:** APPROACH Phase 3 enrollment completed ahead of schedule — 223 adults with moderate-to-severe MDD and inadequate antidepressant response, randomized 1:1 to HLP003 16 mg or placebo, two doses three weeks apart. Primary endpoint is MADRS change from baseline at six weeks; key secondary is MADRS at twelve weeks. A single continuous scale at a fixed timepoint produces a result that resolves.\n- **Company-reported Phase 2 for HLP003** (helus.com program materials): mean ~23-point MADRS reduction twelve months after two 16 mg doses, with 100% response and 71% remission at a MADRS ≤10 benchmark. HLP003 carries FDA Breakthrough Therapy Designation, which is an agency-level read on that effect size.\n- **Leadership build-out inside 16 days:** Michael Halstead, former president of Intra-Cellular Therapies, appointed CEO 2026-08-03; Regina Donohue named Chief People Officer and Suresh Durgam, M.D. added to the Scientific Advisory Board on 2026-08-18. Commercial-stage hiring ahead of data is a resourcing commitment.\n- **2026-08-14 (fiscal Q1 2027, quarter ended 2026-06-30):** cash $166.4M against $37.1M of operating cash used in the quarter. The release carries no runway statement; those two figures are the checkable items.\n\n## Bear Case\n- **The re-rating carries no new efficacy information.** Nothing about HLP003's data has been disclosed since 2026-07-21. TD Cowen's own prior mark was $8, and its 2026-08-20 reasons are timing, personnel and sector newsflow. A view that moves 7.75x on non-clinical inputs can move back on the same class of inputs.\n- **The marks disagree by an order of magnitude.** Wells Fargo initiated Overweight at $16 on 2026-07-27; TD Cowen posted $62 twenty-four days later; H.C. Wainwright holds $70 and Canaccord $42. A range of $8.15 to $70.45 is coverage disagreeing on probability of success, and the quote is tracking the top of it.\n- **Adjunctive MDD is where placebo arms do the damage.** The primary is a six-week MADRS delta in patients already stabilised on antidepressants. Phase 2 separation in this class has repeatedly failed to survive placebo-controlled scale.\n- **Burn is accelerating.** Fiscal Q1 2027 net loss $47.8M versus $24.6M a year earlier; operating cash use $37.1M versus $29.5M. The 2026-06-24 underwritten secondary cleared 10.3M shares at $4.85 for roughly $50M gross — the same financing option now exists at a far higher price, and coverage of the 2026-08-20 note tied that raise to execution of a second Phase 3, EMBRACE.\n- **The Q1 print is scored both ways.** Benzinga recorded EPS of $(0.91) as a beat against a $(1.07) estimate; a separate compiler carried consensus at $(0.855), which makes the same number a miss. Cash is the line that is not compiler-dependent.\n- **No US insider-transaction record exists by construction.** As a foreign private issuer reporting on Form 6-K with insiders filing to Canada's SEDI, the standard screen for selling into strength returns nothing — the absence is a data gap.\n\n## Setup & Price Structure\n- **2026-08-21 close $12.59 — the 52-week high, 0.0% below it.** RSI(14) 76.2. Three-month price change of +169%.\n- **Nothing beneath.** The last published trend marks are a 50-day average of $6.98 and a 200-day of $6.31 (2026-08-15). Both are rising and both are stale by a week, but no consolidation zone was built between them and the current quote.\n- **The near shelf is thin and recent.** Coverage of the 2026-08-20 note cited a pre-hike quote of $11.78 and a then-52-week high of $12.05; the 2026-08-14 close was $11.99. Roughly one dollar of range holds the entire post-hike structure.\n- **Crowding observables:** a single analyst note produced a ~6% session on 2026-08-20; the name has been clustering in Benzinga movers screens (2026-08-10 pre-market decliners list); RSI(14) at 76.2 with the close at the high. Float is 46.84M of 61.98M shares outstanding (2026-08-15), so a small dollar flow moves the print in either direction.\n- **What is not crowded:** short interest at 6.73% of float and a short ratio of 1.99 (2026-08-15) leave little mechanical fuel. Upside from here has to come from new buyers rather than from covering.\n\n## Catalyst Calendar (next 30 days)\n\n- **2026-08-23 to 2026-09-22 — no dated company event on the public calendar.** The fiscal Q1 print (2026-08-14) and the target revision (2026-08-20) have passed. Any move in this window is unscheduled: cohort rotation, sector newsflow, or an unannounced release.\n- **~2026-11-13 (est.) — fiscal Q2 2027 report** (September quarter; fiscal year ends 31 March). First scheduled opportunity for management to confirm or move the topline date and update the $166.4M cash figure.\n\n## Elapsed catalysts\n\n- **~mid-November 2026 (TD Cowen, 2026-08-20) / Q4 2026 (company guidance, 2026-07-21) — APPROACH Phase 3 topline for HLP003.** The event the equity is priced against. *(passed 6d ago)*\n\n## What Would Change Our Mind\nThe leg being bought is a run into a dated readout on a Breakthrough-designated asset, underwritten by a target revision rather than by data. It breaks on any of three observables. First, timing: if the ~2026-11-13 fiscal Q2 release restates topline as 2027, or a 6-K cites database-lock or data-cleaning delay, the dated-binary frame is gone and the name reverts to the no-calendar flow structure it had in July. Second, financing: a prospectus supplement, ATM drawdown or underwritten offering priced at a discount to the prevailing quote before the readout repeats the 2026-06-24 pattern at a higher share count. Third, structure: a weekly close below $11.78 gives back the level the 2026-08-20 move launched from, and there is no published support beneath it until the rising 50-day average near $6.98 — a break of that shelf with no company news would date the accelerating label as expired. On the other side, a company release confirming a specific November topline date, or a fourth shop initiating above the current quote, extends the leg.\n\n## Correlation Notes\n- **Cohort beta is explicit in the bull note.** One of TD Cowen's three stated reasons on 2026-08-20 was sector-level M&A, regulatory and executive-branch developments, none of it company-specific. Part of this re-rating is class beta and will grade as such: if ATAI and CMPS did not re-rate over the same window, the sector reason was thin.\n- **2026-07-16:** HELP printed as a gainer alongside ATAI and CMPS in two separate screens. Single-name analysis of this ticker understates the shared factor.\n- **Two listings, one company.** The Nasdaq line and the Canadian HELP.NE line can diverge intraday on FX and liquidity; screens quoting one are not quoting the other.\n- **Small-cap clinical biotech beta.** With no revenue and a binary roughly three months out, the discount rate matters more than any operating variable; rate-driven XBI drawdowns hit this name without a company headline.",
  "first_seen": "2026-06-30",
  "last_analyzed": "2026-08-24T06:11:46+00:00",
  "last_synthesized": "2026-08-23",
  "last_update_source": "theme_discovery",
  "license": "Content © FrontierPicks. Cite the canonical URL."
}